title: Geographic variation and disparity in stimulant treatment of adults and children in the United States in 2008.
abstract: OBJECTIVE This study estimated the prevalence of stimulant treatment among both adults and children at national, state, and county levels during 2008 and explored explanations for wide variations in treatment prevalence. METHODS Records of 24.1 million stimulant prescriptions dispensed to insured and uninsured patients were obtained from approximately 76% of U.S. retail pharmacies. Data were weighted to estimate treatment prevalence on March 15, 2008, for all U.S. states and counties. Regression models were used to estimate the associations among the counties' treatment rates and the characteristics of the counties and their resident populations. RESULTS An estimated 2.5% of children ≤ 17 years of age (3.5% of males and 1.5% of females) and .6% of persons >17 years of age were being treated with stimulants in March 2008. Treatment prevalence among states varied widely, and variation among counties was even wider. Two-thirds of the variation among counties in treatment prevalence was associated with supply of physicians, socioeconomic composition of the population, and, among children, funding for special education. Rates of children and adults in treatment were highly correlated. CONCLUSIONS Wide variations in treatment prevalence signal disparities between established clinical practice guidelines and actual practice, especially for primary care, where most patients prescribed stimulants are managed. Better education and training for physicians may improve identification and treatment, thereby reducing disparities in care for attention-deficit hyperactivity disorder and other disabling conditions.
authors.forename: Douglas C
authors.initials: DC
authors.lastname: McDonald
authors.forename: Sarah Kuck
authors.initials: SK
authors.lastname: Jalbert
mesh_terms: D000328:Adult; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D017057:Medically Uninsured / Q000706:statistics & numerical data; D055656:Prescriptions / Q000706:statistics & numerical data*; D015995:Prevalence; D062206:Spatial Analysis; D014481:United States
chemical_list: D000697:Central Nervous System Stimulants
references.citation: BMJ. 2011 Mar 17;342:d1513
references.pmid: 21415111
references.citation: Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):442-9
references.pmid: 22021031
references.citation: Pediatrics. 2000 Oct;106(4):E44
references.pmid: 11015539
references.citation: Pediatrics. 2011 Nov;128(5):1007-22
references.pmid: 22003063
references.citation: World Psychiatry. 2003 Jun;2(2):104-13
references.pmid: 16946911
references.citation: J Child Adolesc Psychopharmacol. 2005 Feb;15(1):44-56
references.pmid: 15741785
references.citation: Arch Pediatr Adolesc Med. 2007 Sep;161(9):857-64
references.pmid: 17768285
references.citation: Psychiatr Serv. 2009 Aug;60(8):1075-83
references.pmid: 19648195
references.citation: J Am Acad Child Adolesc Psychiatry. 2004 May;43(5):559-67
references.pmid: 15100562
references.citation: J Pain. 2012 Oct;13(10):988-96
references.pmid: 23031398
references.citation: J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):737-44
references.pmid: 9183127
references.citation: J Dev Behav Pediatr. 2000 Oct;21(5):322-31
references.pmid: 11064959
references.citation: Child Adolesc Psychiatr Clin N Am. 2000 Jul;9(3):541-55, vii
references.pmid: 10944656
references.citation: Am J Psychiatry. 2006 Apr;163(4):716-23
references.pmid: 16585449
references.citation: Am J Psychiatry. 2003 Jun;160(6):1071-7
references.pmid: 12777264
references.citation: MMWR Morb Mortal Wkly Rep. 2005 Sep 2;54(34):842-7
references.pmid: 16138075
references.citation: J Am Acad Child Adolesc Psychiatry. 2000 Aug;39(8):975-84; discussion 984-94
references.pmid: 10939226
references.citation: Med Care. 1993 May;31(5 Suppl):YS37-44
references.pmid: 8492584
references.citation: J Atten Disord. 2007 May;10(4):335-42
references.pmid: 17449832
references.citation: MMWR Suppl. 2011 Jan 14;60(1):1-2
references.pmid: 21430612
references.citation: Health Policy. 2006 Dec;79(2-3):221-30
references.pmid: 16473435
references.citation: Br J Psychiatry. 2007 May;190:402-9
references.pmid: 17470954
references.citation: Am J Psychiatry. 2012 Feb;169(2):160-6
references.pmid: 22420039
references.citation: JAMA. 2004 Aug 4;292(5):619-23
references.pmid: 15292088
references.citation: N Engl J Med. 2010 Nov 18;363(21):1985-8
references.pmid: 21047217
references.citation: Child Adolesc Psychiatr Clin N Am. 2000 Jul;9(3):711-26
references.pmid: 10944664
references.citation: Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):267-75
references.pmid: 15386704
references.citation: J Am Acad Child Adolesc Psychiatry. 1990 Jul;29(4):526-33
references.pmid: 2387786
references.citation: Pediatrics. 2003 Feb;111(2):237-43
references.pmid: 12563045
references.citation: Int J Psychiatry Med. 2010;40(4):363-82
references.pmid: 21391408